Case Report

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma

Tamim Alsuliman,1,2 Maifa Belghoul,3 and Bachra Choufi 1

1Service d’Hématologie, Centre Hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, France
2Service d’Hématologie, Centre Hospitalier Régionale Universitaire de Lille, Lille, France
3Augsburg College, Minneapolis, MN, USA

Correspondence should be addressed to Bachra Choufi; b.choufi@gmail.com

Received 10 May 2018; Revised 17 July 2018; Accepted 30 July 2018; Published 16 August 2018

1.Introduction

Nowadays, mantle cell lymphoma is considered to have one of the worst prognostic profiles among lymphoid malignancies [1]. Its treatment is not widely uniformed [2]. High-dose aracytine, intensive chemotherapy followed by stem cells reinjection, rituximab maintenance, and more recently Bruton’s tyrosine kinase (BTK) inhibitors are often the most frequently used elements in the therapeutic arsenal [3].

Mantle cell lymphoma (MCL) rarely affects the central nervous system (CNS). Indeed, the occurrence of mantle cell lymphoma in the CNS represents about 0.9% of all diagnosis of mantle cell lymphoma and 4% of recurrent cases [4]. This type of localization is typically observed in high proliferating forms of MCL. CNS localization can involve many serious complications such as loss of consciousness [5]. There is no consensus on its treatment, and its survival is about 3–5 months after diagnosis [6]. Additionally, the efficacy of CNS prophylaxis, which typically includes aracytine and autologous stem cell transplantation, is yet to be proven. [7].

2. Patient and Method

This work was conducted with respect to the Helsinki declaration. Informed consent for the publication of this article was obtained from the patient.

This is a case of a 69-year-old male diagnosed with mantle cell lymphoma.

Ibrutinib was used at a daily dose of 560 mg, using a nasogastric standard feeding tube.
3. The Case

A 69-year-old male was diagnosed in 2006 with classical mantle cell lymphoma, Ki67 positive (cells positivity was close to 30%), involving the lymph nodes and the bone marrow. The patient was treated initially by 8 cycles of R-CHOP (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and vincristine 1.4 mg/m² for a maximum dose of 2 mg), leading to a complete remission, and this treatment was applied following our local institutional guidelines for alternative treatments due to patient’s refusal of ASCT at the moment.

Two years later, the patient had his first relapse with a nodal localization. The patient was treated with rituximab and high-dose aracynine-based immune-chemotherapy regimen (R-DHAP: rituximab, dexamethasone, cytarabine, and cisplatin) followed by autologous stem cell transplantation leading to a second complete remission.

Two years later, the patient was diagnosed with recurrent mantle cell lymphoma, treated this time with six cycles of rituximab and bendamustine combination therapy, and ended up in complete remission for the third time.

By August 2015, nearly 4 years after this third line of treatment, a significant right axillary nodal mass measuring 5 × 7 cm at its largest axes was discovered during his routine follow-up exam. A surgical biopsy and a pathological examination were carried out revealing MCL recurrence, with the same histological characteristics, and ibrutinib as a salvage therapy was prescribed shortly afterwards.

However, the patient was admitted in the neurology department due to a suspicion of cerebrovascular accident just prior to treatment initiation. A complete neurological exam was negative, and the patient was discharged with a prescription of aspirin. Fifteen days after his discharge from the hospital, the patient was admitted again secondary to a sudden onset of vertigo associated with a progressive loss of consciousness. Magnetic resonance imaging and a lumbar puncture revealed no obvious abnormalities. Extensive neurological and cardiovascular investigations were launched with no obvious pathology. Given the rapid degradation of the patient’s neurological status followed by a deep coma state during his hospitalization, we decided to initiate ibrutinib treatment via the nasogastric tube at a daily dose of 560 mg. Two days later, the patient regained full consciousness, and 10 days later, he was discharged from the hospital.

Additional workup during the patient’s follow-up appointments rejected all the other hypotheses (cerebrovascular accident, neuromeningitis, and focal lesions) behind the patient’s neurological situation.

The patient was in complete remission after receiving ibrutinib and had no signs of neurological involvement for 24 months after the initiation of ibrutinib. However, after these two years, he developed a recurrent disease, with the same pathology (MCL), and a nodal localization. Currently, he is under treatment with RibVBD regimen (rituximab, bendamustine, Velcade, and dexametasone).

4. Discussion

To the best of our knowledge, this is the first case published describing the administration of ibrutinib through a nasogastric tube to a comatose patient. It is worth noting, however, that one case was reported describing the administration of ibrutinib capsule content through the nasogastric tube in a conscious patient with a swallowing disorder [8].

Although the manufacturer has already declared that this method of administration is not recommended, we found one on-going clinical trial comparing suspension and sprinkle formulations of ibrutinib to the capsule formulation (NCT02390609). However, the results for this study have not been released yet [9]. We believed, regarding the critical situation, that this mode of delivery of the drug could represent the last chance for this patient.

Ibrutinib’s tyrosine kinase is an essential component of B-cell receptor signalling which mediates the interaction between the tumor microenvironment and promotes the survival and proliferation of B-cells. Ibrutinib is the Bruton tyrosine kinase (BTK) inhibitor that acts against B-cell malignancies promoting inhibition of proliferation-inducing apoptosis [10]. Central nervous system (CNS) dissemination occurs in 4.1% of patients with mantle cell lymphoma, and median survival is of average 3 months [4, 11].

CNS localization of mantle cell lymphoma is a dramatic incident, and without ibrutinib, we believe that the patient would have died. Sophie Bernard and Catherine Thieblemont are among the first to have reported their experience with the use of ibrutinib to treat CNS in MCL patients with CNS relapse, showing rapid positive clinical response within 3 to 8 days, with certain patients having a higher ibrutinib plasma exposure on day 8 (AUC 0–24h 3119 ng·h/mL; Cmax 729 ng·mL⁻¹). Ibrutinib concentration was measured in the cerebral spinal fluid to be 1 to 7 percent of plasma concentration, assuming that ibrutinib had reached CSF, though neither the permeability nor the diffusion of ibrutinib through the blood-brain barrier have been well studied. Yet, the mechanism of ibrutinib CSF distribution and its target are still not well understood.

In the aforementioned case series, the survival ranged from some months to a year after CNS relapse diagnosis, and the responses were active at 6 to 12 months of follow-up for two confirmed complete remissions, while a partial response was obtained for the third. In addition, these findings may be discussed along with ibrutinib treatment results of similar situations, as primary CNS lymphoma [12]. Obviously, we could not totally roll out the occurrence of encephalitis mediated by paraneoplastic anti-neuronal antibodies, though the absolute negativity of MRI repeated examinations for any habitual sign of paraneoplastic encephalitis along with the rapid and total resolving of all neurological symptoms after 2 days of ibrutinib initiation and the long MCL history are strongly indicating MCL neurological involvement as the main hypothesis [13].
5. Conclusion

In light of the aforementioned arguments, we believe that the treatment by ibrutinib through the nasogastric tube was a determinant factor in this patient’s survival. However, more studies should be conducted to evaluate the efficacy and safety of this molecule in CNS localization of mantle cell lymphoma and maybe even primary CNS lymphoma.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

[1] J. M. Vose, "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management," *American Journal of Hematology*, vol. 92, no. 8, pp. 806–813, 2017.
[2] K. Maddocks and K. A. Blum, "Treatment strategies in mantle cell lymphoma," *Cancer Treatment and Research*, vol. 165, pp. 251–270, 2015.
[3] C. Viscò, S. Finotto, R. Zambello et al., "Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation," *Journal of Clinical Oncology*, vol. 31, no. 11, pp. 1442–1449, 2013.
[4] C. Y. Cheah, A. George, E. Gine et al., "Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network," *Annals of Oncology*, vol. 24, no. 8, pp. 2119–2123, 2013.
[5] L. G. Gonzalez-Bonet, R. Garcia-Boyero, and J. Gaona-Morales, "Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas," *World Neurosurgery*, vol. 99, pp. 808.e1–808.e2, 2017.
[6] A. Ferrer, F. Bosch, N. Villamor et al., "Central nervous system involvement in mantle cell lymphoma," *Annals of Oncology*, vol. 19, no. 1, pp. 135–141, 2008.
[7] S. Gill, K. E. Herbert, H. M. Prince et al., "Mantle cell lymphoma with central nervous system involvement: frequency and clinical features," *British Journal of Haematology*, vol. 147, no. 1, pp. 83–88, 2009.
[8] J. M. Maddox and M. Majid, "Use of ibrutinib via nasogastric (NG) tube & percutaneous endoscopic gastrostomy (PEG) tube," *Blood*, vol. 128, no. 22, p. 5371, 2016.
[9] E. S. Kim and S. Dhillon, "Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia," *Drugs*, vol. 75, no. 7, pp. 769–776, 2015.
[10] L. A. Honigberg, A. M. Smith, M. Sirisawad et al., "The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 29, pp. 13075–13080, 2010.
[11] S. Bernard, L. Goldwirt, S. Amorim et al., "Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse," *Blood*, vol. 126, no. 14, pp. 1695–1698, 2015.
[12] C. Grommes, A. Pastore, N. Palaskas et al., "Ibrutinib un-masks critical role of Bruton tyrosine kinase in primary CNS lymphoma," *Cancer Discovery*, vol. 7, no. 9, pp. 1018–1029, 2017.
[13] W. Grisol, B. Giometto, R. Vitaliani, and S. Oberndorfer, "Current approaches to the treatment of paraneoplastic encephalitis," *Therapeutic Advances in Neurological Disorders*, vol. 4, no. 4, pp. 237–248, 2011.